Hepatocyte Growth Factor is a Potential Lymphangiogenic Factor; Clinical Implications

Author(s): Wen G. Jiang, Andrew J. Sanders.

Journal Name: Current Signal Transduction Therapy

Volume 6 , Issue 2 , 2011

Become EABM
Become Reviewer

Abstract:

Hepatocyte growth factor (HGF) is a known angiogenic factor that has profound effects on vascular endothelial cells. In recent years, it has been reported that the factor also acts as a lymphagiogenic factor that induces lymphangenesis from lymphatic endothelial cells. The current article debates some of the recent evidence showing such an effect and also discusses the clinical studies that link to lymphatic related conditions, together with clinical implications.

Keywords: Hepatocyte growth factor, lymphangiogenesis, endothelial cells, VEGF, melanoma, cMET, lymph node metastases, prostate cancer, lymphatic invasion, metastasis, squamous cell carcinoma, lymphatic microvessel density, LYVE-1, Prox-1, VEGF-R3, breast cancer, HGF antagonist, in vivo tumour models, D2-40 antibody, MW 40K, ERK, akt, PECAM

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 2
Year: 2011
Page: [168 - 172]
Pages: 5
DOI: 10.2174/157436211795659900
Price: $58

Article Metrics

PDF: 2